Conditional Ablation of Myeloid TNF Improves Functional Outcome and Decreases Lesion Size after Spinal Cord Injury in Mice.
Animals
CX3C Chemokine Receptor 1
/ metabolism
Gene Deletion
Inflammation
/ pathology
MAP Kinase Signaling System
Macrophages
/ metabolism
Mice
Microglia
/ metabolism
Motor Activity
Myeloid Cells
/ metabolism
Neutrophils
/ metabolism
Proto-Oncogene Proteins c-akt
/ metabolism
Recovery of Function
STAT Transcription Factors
/ metabolism
Spinal Cord
/ pathology
Spinal Cord Injuries
/ pathology
Tumor Necrosis Factor-alpha
/ metabolism
bcl-X Protein
/ metabolism
functional outcome
myeloid cells
spinal cord injury
tumor necrosis factor
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
03 11 2020
03 11 2020
Historique:
received:
30
07
2020
revised:
27
10
2020
accepted:
01
11
2020
entrez:
6
11
2020
pubmed:
7
11
2020
medline:
16
6
2021
Statut:
epublish
Résumé
Spinal cord injury (SCI) is a devastating condition consisting of an instant primary mechanical injury followed by a secondary injury that progresses for weeks to months. The cytokine tumor necrosis factor (TNF) plays an important role in the pathophysiology of SCI. We investigated the effect of myeloid TNF ablation (peripheral myeloid cells (macrophages and neutrophils) and microglia) versus central myeloid TNF ablation (microglia) in a SCI contusion model. We show that TNF ablation in macrophages and neutrophils leads to reduced lesion volume and improved functional outcome after SCI. In contrast, TNF ablation in microglia only or TNF deficiency in all cells had no effect. TNF levels tended to be decreased 3 h post-SCI in mice with peripheral myeloid TNF ablation and was significantly decreased 3 days after SCI. Leukocyte and microglia populations and all other cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, and IFNγ) and chemokines (CCL2, CCL5, and CXCL1) investigated, in addition to TNFR1 and TNFR2, were comparable between genotypes. Analysis of post-SCI signaling cascades demonstrated that the MAPK kinase SAPK/JNK decreased and neuronal Bcl-XL levels increased post-SCI in mice with ablation of TNF in peripheral myeloid cells. These findings demonstrate that peripheral myeloid cell-derived TNF is pathogenic in SCI.
Identifiants
pubmed: 33153044
pii: cells9112407
doi: 10.3390/cells9112407
pmc: PMC7692197
pii:
doi:
Substances chimiques
CX3C Chemokine Receptor 1
0
Cx3cr1 protein, mouse
0
STAT Transcription Factors
0
Tumor Necrosis Factor-alpha
0
bcl-X Protein
0
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Exp Neurol. 2000 Nov;166(1):190-5
pubmed: 11031095
Mediators Inflamm. 2016;2016:2684098
pubmed: 28070141
Ann N Y Acad Sci. 2005 May;1042:481-7
pubmed: 15965094
J Neuroimmunol. 1996 Sep;69(1-2):151-6
pubmed: 8823387
J Neurotrauma. 2001 May;18(5):563-8
pubmed: 11393259
Front Neurosci. 2019 Aug 07;13:781
pubmed: 31440125
J Exp Med. 2000 May 15;191(10):1721-34
pubmed: 10811865
Exp Neurol. 2008 Feb;209(2):378-88
pubmed: 17662717
J Neurotrauma. 2001 Jan;18(1):105-14
pubmed: 11200245
Cell Rep. 2017 Jan 3;18(1):198-212
pubmed: 28052249
Shock. 2008 Jan;29(1):32-41
pubmed: 17621255
Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6185-90
pubmed: 18413601
J Neurosci Res. 1998 Aug 1;53(3):368-76
pubmed: 9698165
J Neurosci. 2009 Oct 28;29(43):13435-44
pubmed: 19864556
Exp Neurol. 2014 Apr;254:109-20
pubmed: 24468477
J Neuroinflammation. 2014 Dec 12;11:203
pubmed: 25498129
J Cereb Blood Flow Metab. 2016 Sep;36(9):1553-69
pubmed: 26661199
Cell Death Differ. 2003 Jan;10(1):45-65
pubmed: 12655295
Immunity. 2013 Jan 24;38(1):79-91
pubmed: 23273845
Immunity. 2001 Oct;15(4):533-43
pubmed: 11672536
Neuroscience. 2007 Nov 30;150(1):168-81
pubmed: 17945432
Biochem J. 2003 Jun 1;372(Pt 2):359-69
pubmed: 12614194
J Immunol. 2008 Nov 1;181(9):6481-90
pubmed: 18941239
J Neurotrauma. 1999 Oct;16(10):851-63
pubmed: 10547095
Acta Neuropathol. 2019 May;137(5):785-797
pubmed: 30929040
Acta Neuropathol Commun. 2020 Jun 5;8(1):81
pubmed: 32503645
Neurobiol Dis. 2001 Aug;8(4):590-9
pubmed: 11493024
J Biol Chem. 1999 Aug 6;274(32):22165-9
pubmed: 10428780
J Neurosci. 2009 Feb 4;29(5):1319-30
pubmed: 19193879
Curr Mol Med. 2004 Jun;4(4):439-44
pubmed: 15354874
J Neuroinflammation. 2008 Oct 23;5:46
pubmed: 18947400
Science. 2010 Nov 5;330(6005):841-5
pubmed: 20966214
J Neurotrauma. 2003 Feb;20(2):207-19
pubmed: 12675973
Eur Spine J. 2012 Dec;21(12):2588-93
pubmed: 22526707
Immunity. 2005 Jan;22(1):93-104
pubmed: 15664162
Nat Neurosci. 2017 Jun;20(6):793-803
pubmed: 28414331
Neuron. 2014 Sep 3;83(5):1098-116
pubmed: 25132469
J Neuroinflammation. 2014 Sep 10;11:159
pubmed: 25204558
J Comp Neurol. 2007 Jan 10;500(2):267-85
pubmed: 17111361
Brain Behav Immun. 2010 Oct;24(7):1054-7
pubmed: 20149864
J Neurotrauma. 2006 May;23(5):635-59
pubmed: 16689667
J Biol Chem. 2000 Jan 7;275(1):322-7
pubmed: 10617621
Spine (Phila Pa 1976). 2011 Aug 1;36(17):1350-8
pubmed: 21224756
Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9450-5
pubmed: 12082184
FEBS Lett. 2003 Mar 13;538(1-3):41-7
pubmed: 12633850
Nat Commun. 2019 Jan 31;10(1):518
pubmed: 30705270
Sci Rep. 2016 Jul 07;6:29291
pubmed: 27384243
J Neurosci. 2001 Sep 1;21(17):6617-25
pubmed: 11517251
J Pharmacol Exp Ther. 2006 Mar;316(3):1006-16
pubmed: 16303916